Jupiter Asset Management Ltd. Acquires Shares of 20,362 IDEXX Laboratories, Inc. $IDXX

Posted by Geri Gentry on May 30th, 2026

Jupiter Asset Management Ltd. bought a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 20,362 shares of the company’s stock, valued at approximately $13,776,000.

Other hedge funds have also made changes to their positions in the company. Elyxium Wealth LLC bought a new position in IDEXX Laboratories during the 4th quarter valued at about $3,666,459,000. Northwestern Mutual Wealth Management Co. grew its stake in IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after buying an additional 1,442,174 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IDEXX Laboratories by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock worth $555,802,000 after buying an additional 326,348 shares in the last quarter. Zurich Insurance Group Ltd FI bought a new position in shares of IDEXX Laboratories in the third quarter valued at approximately $143,730,000. Finally, AustralianSuper Pty Ltd raised its stake in shares of IDEXX Laboratories by 213.1% in the fourth quarter. AustralianSuper Pty Ltd now owns 300,197 shares of the company’s stock valued at $203,092,000 after acquiring an additional 204,307 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the transaction, the executive vice president owned 18,141 shares of the company’s stock, valued at $11,511,734.37. This trade represents a 8.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Down 0.8%

IDXX stock opened at $563.53 on Friday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a market cap of $44.45 billion, a P/E ratio of 41.50, a PEG ratio of 3.30 and a beta of 1.58. The business has a fifty day moving average of $564.58 and a 200-day moving average of $637.19.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities research analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on IDXX. BTIG Research decreased their price target on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating on the stock in a research report on Tuesday, February 3rd. Barclays reduced their price objective on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. UBS Group decreased their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a report on Tuesday, April 28th. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

View Our Latest Report on IDXX

About IDEXX Laboratories

(Free Report)

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.